Astrazeneca Share News (AZN)

AstraZeneca hails trial results of cancer drugs Imfinzi and Tagrisso

(Alliance News) - AstraZeneca PLC on Thursday hailed phase 3 trial results on its lung cancer drugs Imfinzi and Tagrisso.

AstraZeneca's Imfinzi trial shows 'significantly improved' event-free survival rates

(Sharecast News) - Drugmaker AstraZeneca said on Thursday that results from a phase III trial on its resectable non-small cell lung cancer treatment had shown a "significantly improved" event-free survival.

UK stock indexes close down after Powell's hawkish remarks

Premier Foods climbs on annual profit outlook raise

*

Miners drag FTSE 100 lower on China concerns

Clarkson up on upbeat annual profit

*

TOP NEWS: AstraZeneca hails Enhertu phase 2 trial results

(Alliance News) - AstraZeneca PLC on Monday hailed phase 2 trial results of its cancer drug Enhertu, which it develops with Daiichi Sankyo Co Ltd.

LONDON BRIEFING: Stocks called flat; AstraZeneca positive test results

(Alliance News) - Stocks in London were called to open flat on Monday, as the dollar softened ahead of a consequential week for US economic data and monetary policy guidance.

AstraZeneca, Daiichi's Enhertu hits trial targets

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has met prespecified targets in a phase 2 trial the companies said on Monday.

Viatris warns it will stop selling essential drugs in UK without changes to drug pricing agreement

LONDON, March 2 (Reuters) - Drugmaker Viatris Inc warned on Thursday that it will stop selling some essential medicines in the UK that are already in short supply unless the British government makes changes to its voluntary medicines pricing agreement.

US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo

(Alliance News) - AstraZeneca PLC and Merck & Co Inc said on Thursday that the US Food & Drug Administration will convene a meeting of the Oncologic Drugs Advisory Committee to discuss the supplemental new drug application for Lynparza in combination with abiraterone and prednisone or prednisolone.

IN BRIEF: AstraZeneca prices three tranche global bond offering

AstraZeneca PLC - Cambridge, UK-based pharmaceuticals firm - Announces wholly owned subsidiary AstraZeneca Finance prices a three tranche global bond offering totalling USD2.25 billion on February 28. Expects offering to close on March 3. Says the notes issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by AstraZeneca are USD1.1 billion of fixed rate notes with a coupon of 4.875%, maturing March 3 2028, USD650 million of fixed rate notes with a coupon of 4.900%, maturing March 3 2030, and USD500 million of fixed rate notes with a coupon of 4.875%, maturing March 3, 2033. Expects to use the net proceeds of the offering for general corporate purposes, which may include the refinancing of existing indebtedness.

TOP NEWS: AstraZeneca closes CinCor buy; Enhertu wins Chinese approval

(Alliance News) - AstraZeneca PLC on Friday reported that it completed the acquisition of CinCor Pharma Inc, which focuses on hypertension and chronic kidney disease, while its cancer drug Enhertu won another approval, its first in China.

Upbeat corporate guidances lift European shares, Nvidia forecast boosts chip stocks

UK healthcare giants fall on ex-dividend trades

*

FTSE 100 slips as ex-dividend trades weigh, Rolls-Royce soars

Rolls-Royce jumps on upbeat forecast

*

LONDON MARKET CLOSE: FTSE 100 struggles, but European peers rise

(Alliance News) - Stock prices in London closed mixed on Thursday, with blue-chips ending in the red on renewed concerns of higher rates in the US, as well as a host of stocks going ex-dividend.

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.